AI ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ÇÁ·Î¹ÙÀÌ´õ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Ä¡·á ¿ëµµº°, ÀÓ»ó½ÃÇè ´Ü°èº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
AI-based Clinical Trials Solution Provider Market Size, Share & Trends Analysis Report By Therapeutic Application, By Clinical Trial Phase, By End-use, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1571821
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 118 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

AI ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ÇÁ·Î¹ÙÀÌ´õ ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é AI ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç Á¦°ø ¾÷ü ¼¼°è ½ÃÀå ±Ô¸ð´Â ¿¹Ãø ±â°£ µ¿¾È CAGR 22.1%¸¦ ±â·ÏÇÏ¿© 2030³â±îÁö 78¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

AI´Â ´ÙÀç´Ù´ÉÇÑ µµ±¸·Î, ¾à¹° ¿¬±¸ ¿î¿µÀÇ È¿À²¼ºÀ» ³ôÀÌ°í ½Å¾à °³¹ß ÇÁ·Î¼¼½º¸¦ °¡¼ÓÈ­Çϱâ À§ÇØ È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀǾàǰ °³¹ß ÇÁ·Î¼¼½ºÀÇ ºñ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ´Â µ¥¿¡µµ Å©°Ô Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ Çаè¿Í Á¦¾à»çµéÀº AI ±â¹Ý Ç÷§Æû°ú ±â¼úÀ» Àû±ØÀûÀ¸·Î µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 1¿ù ¹ÙÀÌ¿¤Àº ¿µ±¹¿¡ ±â¹ÝÀ» µÐ AI ±â¹Ý ½Å¾à°³¹ß ȸ»ç¿Í ÆÄÆ®³Ê½ÊÀ» ü°áÇϰí AI ½Å¾à°³¹ß Ç÷§ÆûÀ» Ȱ¿ëÇÑ Ãʱ⠿¬±¸ ÇÁ·ÎÁ§Æ®¸¦ ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¬±¸°³¹ßÀ» ÃËÁøÇÏ´Â ¹Î°ü Çù·Â°ú AI°¡ ÀǾàǰ ¿¬±¸ ºÐ¾ß¿¡¼­ Á¦°øÇÏ´Â ´Ù¾çÇÑ ÀÀ¿ë ºÐ¾ß°¡ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ÀÓ»ó½ÃÇè ´Ü°èº°·Î º¸¸é ÀÓ»ó 2»óÀÌ 2023³â 45.5%ÀÇ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ½Å¾à °³¹ß °Ç¼öÀÇ Áõ°¡¿Í ÀÓ»ó 2»ó ½ÃÇèÀÌ È°¹ßÈ÷ ÁøÇàµÇ°í Àֱ⠶§¹®À¸·Î ºÐ¼®µË´Ï´Ù. ¶ÇÇÑ, ÀÌ ´Ü°èÀÇ ÀÓ»ó½ÃÇèÀ» ÅëÇØ µ¥ÀÌÅ͸¦ ¼öÁýÇÏ°í ¿øÇÏ´Â Àüü °á°ú¸¦ Áï°¢ÀûÀ¸·Î ºÐ¼®Çϱâ À§ÇØ AI ±â¹Ý ÅøÀ» äÅÃÇÏ´Â »ç·Ê°¡ Áõ°¡Çϸ鼭 ÀÌ ºÎ¹®ÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ ´Ü°è¿¡¼­´Â AI ±â¹Ý µµ±¸¿¡ ´ëÇÑ °³¼±, °áÁ¤ ¹× °ËÁõÀ» ÅëÇØ AI ±â¹Ý µµ±¸¿¡ ´ëÇÑ Á¶Ä¡¸¦ °³¼±, °áÁ¤ ¹× °ËÁõÇÒ ¼ö Àֱ⠶§¹®¿¡ ÀÌ ºÎ¹®Àº ´õ ³ôÀº ¼öÀÍ Á¡À¯À²À» À¯ÁöÇϰí ÀÖ½À´Ï´Ù.

2023³â AI ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ÇÁ·Î¹ÙÀÌ´õ ½ÃÀå¿¡¼­ Á¾¾çÇÐ ºÐ¾ß°¡ Ä¡·á ¸ñÀû¿¡ µû¶ó °¡Àå ³ôÀº ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¾ÏÀÇ À¯º´·üÀÌ Áõ°¡Çϰí Á¾¾çÇÐ ºÐ¾ßÀÇ ¾à¹° ¿¬±¸ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó AI¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ±â¼ú äÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¡Á¡ ´õ ¸¹Àº ¾÷üµéÀÌ Ã·´Ü Á¾¾çÇÐ ±â¹Ý AI ÅøÀ» °³¹ßÇÏ¿© ¾à¹° ¿¬±¸¿¡ µµÀÔÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

2023³â Á¦¾àȸ»ç´Â ÃÖÁ¾ ¿ëµµ ±â¹Ý ½ÃÀå¿¡¼­ °¡Àå ³ôÀº ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÁÖ¿ä Á¦¾à ȸ»çÀÇ ½Å¾à Ç¥Àû ½Äº°, ½Å¾à °³¹ß ¹× ½Å¾à Å×½ºÆ®ÀÇ Àüü ÇÁ·Î¼¼½º, Áø´Ü ¹× ¹ÙÀÌ¿À ¸¶Ä¿ÀÇ ´õ ³ªÀº °³¹ßÀ»À§ÇÑ AI ±â¹Ý ±â¼úÀÇ Ã¤Åà Áõ°¡´Â ºÎ¹® ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ÀÌµé ´ëÇü Á¦¾à»çµéÀº AI º¥´õ¿Í Çù·ÂÇÏ¿© Àüü R&D ¹× ½Å¾à °³¹ß ÇÁ·Î¼¼½º¿¡ AI ±â¼úÀ» Ȱ¿ëÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì°¡ 2023³â 43.4%ÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ìÀ§´Â ÀÌ Áö¿ªÀÇ ½ºÅ¸Æ®¾÷ ¼ö°¡ Áõ°¡Çϰí Àֱ⠶§¹®À¸·Î ºÐ¼®µË´Ï´Ù. ¿¹¸¦ µé¾î, Bullfrog AI´Â ¹Ì±¹¿¡ º»»ç¸¦ µÐ ½ºÅ¸Æ®¾÷À¸·Î Á¤¹Ð ÀǷḦ °¡´ÉÇÏ°Ô ÇÏ´Â ÀÚü AI Ç÷§ÆûÀÎ bfLEAPÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AI ±â¹Ý ±â¼ú¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í Á¦¾à ¿¬±¸ ¼º°ú¸¦ Çâ»ó½Ã۱â À§ÇØ AI¸¦ µµÀÔÇÏ´Â »ç·Ê°¡ Áõ°¡Çϸ鼭 ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤ºÎ Áö¿øÃ¥°ú ÁÖ¿ä ±â¾÷µéÀÇ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê°¡ Áõ°¡Çϸ鼭 ÀÌ Áö¿ªÀÇ AI ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

AI ±â¹Ý ±â¼úÀº COVID-19 »çÅ·ΠÀÎÇØ äÅÃÀÌ ±ÞÁõÇß½À´Ï´Ù. ÀÌó·³ ÀǾàǰ °³¹ß ¹× ¸ðÁýµÈ ȯÀÚ µ¥ÀÌÅÍ ºÐ¼®À» À§ÇÑ ±â¼úÀûÀ¸·Î Áøº¸µÈ ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϸ鼭 AI ±â¹Ý ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ ±ÞÁõÇÑ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¶ÇÇÑ, ÆÒµ¥¹Í ±â°£ µ¿¾È ¸¹Àº ÀǾàǰ °³¹ß ÇÁ·Î¼¼½º°¡ º¸·ùµÇ¾ú½À´Ï´Ù. ÀÌ¿¡ µû¶ó ½ÃÀåÀÇ ¸¹Àº ÁÖ¿ä ±â¾÷µéÀÌ AI ±â¹Ý ¼Ö·ç¼Ç Ȱ¿ë¿¡ ÁßÁ¡À» µÎ¾î ºÐ»êÇü ÀÓ»ó½ÃÇèÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀ» ÅëÇØ ´ë·®ÀÇ È¯ÀÚ µ¥ÀÌÅ͸¦ È¿°úÀûÀ¸·Î ºÐ¼®ÇÒ ¼ö ÀÖ´Ù´Â Á¡µµ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇß½À´Ï´Ù.

AI ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ÇÁ·Î¹ÙÀÌ´õ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå AI ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ÇÁ·Î¹ÙÀÌ´õ ½ÃÀå : Ä¡·á ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå AI ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ÇÁ·Î¹ÙÀÌ´õ ½ÃÀå : ÀÓ»ó½ÃÇè ´Ü°è ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå AI ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ÇÁ·Î¹ÙÀÌ´õ ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå AI ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ÇÁ·Î¹ÙÀÌ´õ ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®, Ä¡·á ¿ëµµº°, ÀÓ»ó½ÃÇè ´Ü°èº°, ÃÖÁ¾ ¿ëµµº°

Á¦8Àå °æÀï »óȲ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

AI-based Clinical Trials Solution Provider Market Growth & Trends:

The global AI-based clinical trials solution provider market size is expected to reach USD 7.8 billion by 2030, registering a CAGR of 22.1% during the forecast period, according to a new report by Grand View Research, Inc.. AI is a versatile tool and is being increasingly utilized to improve the operational efficacy of drug studies and accelerate the drug discovery process. Also, it is highly adopted to minimize the cost of the drug development process. Various academia and pharmaceutical companies are actively adopting AI-based platforms and technologies. For instance, in January 2020, Bayer entered into a partnership with an AI-driven drug discovery company based in the UK to work on early research projects using the AI drug discovery platform. Furthermore, the initiatives by the public and private sectors to boost the R&D coupled with the diverse applications provided by AI in the field of drug studies are impelling the growth.

Based on the phase of the clinical trial, Phase II dominated the market with a share of 45.5% in 2023 owing to the rising number of drug discoveries and a large number of studies active in the second phase. Moreover, the increasing adoption of AI-based tools for the collection of data and the analysis of immediate outcomes of the overall desired outcome through the clinical trials in this phase is contributing to the segment growth. Furthermore, the segment holds a higher revenue share as the improvement, determination, and validation of measures with respect to the AI-based tool can be carried out in this phase.

In 2023, based on therapeutic applications, oncology accounted for the highest revenue share in the AI-based clinical trials solution provider market. The increasing prevalence of cancer across the globe and the rising number of drug studies in the field of oncology is contributing to the adoption of AI enables technologies. Also, an increasing number of players are developing and adopting advanced oncology-based AI tools for drug studies, thereby propelling the segment growth.

In 2023, pharmaceutical companies accounted for the highest revenue share in the market, based on end-use. The rising adoption of AI-based technologies for the better development of diagnostic and biomarkers, to identify the new drug target and the overall process of drug development and drug trials by major pharmaceutical players is one of the major factors contributing to the segment growth. Moreover, these major pharmaceutical players are collaborating with the AI vendor for leveraging the AI technology for R&D and the overall drug discovery process, thereby, impelling the growth.

North America dominated the market and accounted for a revenue share of 43.4% in 2023. This dominance is attributed to the rising number of start-ups in the region. For instance, Bullfrog AI is a U.S.-based startup that develops bfLEAP, a proprietary AI platform to enable precision medicine. Also, the growing awareness of AI-based technologies and their adoption to enhance the drug studies' outcomes is impelling the market growth in the region. Furthermore, the supportive government initiatives and increasing strategic initiatives by major players are driving the demand for AI-based clinical trial solutions in the region.

The AI-based technologies witnessed a surge in their adoption due to the outbreak of COVID-19. This increasing adoption of technologically advanced solutions for drug development and for the analyses of the recruited patient's data contributed to the upsurge in the adoption of AI-enabled solutions. Moreover, many drug development processes were on hold during the pandemic. Therefore, many key companies in the market shifted their focus on the utilization of AI-based solutions, thereby boosting decentralized drug trials. Furthermore, the effective analysis of a large amount of patient data through these solutions supported the market growth.

AI-based Clinical Trials Solution Provider Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends & Scope

Chapter 4. AI-Based Clinical Trials Solution Providers Market: Therapeutic Applications Estimates & Trend Analysis

Chapter 5. AI-Based Clinical Trials Solution Providers Market: Clinical Trial Phase Estimates & Trend Analysis

Chapter 6. AI-Based Clinical Trials Solution Providers Market: End Use Estimates & Trend Analysis

Chapter 7. AI-Based Clinical Trials Solution Providers Market: Regional Estimates & Trend Analysis, By Therapeutic Applications, By Clinical Trial Phase, By End Use

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â